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Abstract. Using the combined application of L-arginine with HMG-Co-A reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of 
modeling of sepsis-induced disease through the introduction of strain 603 Staphylococcus aureus 
shows endotelio- and cardioprotective effects, manifesting itself in preventing the proliferation of 
endothelial dysfunction coefficient (CED), adrenoreactivity, maintenance of myocardial reserve 
and the normalization of biochemical markers values (Total NO, eNOS expression, C-reactive 
protein, IL-6, TNF). In this case, the combined therapy was so effective that the values obtained 
thereunder did not differ from those obtained from control animals. 
Keywords: endothelial dysfunction, HMG-Co-A reductase inhibitor simvastatin, atorvastatin, 
rosuvastatin, endotoxin. 
 
Introduction: Recently, the abdominal surgery 
has paid much attention to endotoxin-induced lesions 
of the cardiovascular system and the development of 
endothelial dysfunction [1, 2, 3, 4]. At the same time, 
a clear sequence of events lines up: endotoxin-
induced shock with multiorgan pathology, -> release 
of pro-inflammatory cytokines ->, endothelial 
dysfunction -> systemic vasculitis ->, increase in 
vascular and endothelial permeability for 
lymphocytes ->, hyperlipoproteinemia ->, the 
beginning of atherosclerosis [1, 2, 3, 4]. 
It is reasonable to assume that the same 
algorithm can be adopted for any endotoxin-induced 
pathology, regardless of its causes, and subjuct to the 
critically increased levels of pro-inflammatory 
cytokines [5, 6]. 
At the same time, despite the oderliness of 
pathogenic schemes and incorporation of many 
factors (VEGF, sFlt-1 angiotensin II autoantibody 
(type 1) (AT1-AA), cytokines (tumor necrosis factor 
(TNF)-α), endothelin, reactive oxygen species (of 
ROS), thromboxane, 20-hydroxyeicosatetraenoic acid 
(20-HETE), increased sensitivity to angiotensin II, 
etc.), there is an obvious immaturity of 
pharmacological approaches aimed at correction of 
endothelial dysfunction in acute systemic 
inflammation. In this respect, the pharmacological 
target “ADMA-eNOS” is of great interest [7-13].  
We can assume that one of pharmacotherapeutic 
strategies for correction of endotoxin-induced 
endothelial dysfunction is the combined use of  
HMG-Co-A reductase inhibitors [14] and the  
NO donor – L-arginine [15]. 
Methods: Experiments were conducted on white 
male Wistar rats weighing 200-250 g.  
Modeling of endotoxin-induced endothelial 
dysfunction (EIED) was carried out by subcutaneous 
injection of 0.1 ml of fresh suspension Staphylococcus 
aureus (strain 603) at a concentration of 10 bil 
microbial bodies per 1 ml.  
HMG-Co-A reductase inhibitors in combination 
with L-arginine 200 mg/kg were administered 
intragastrically daily for 7 days. All animals were 
divided into experimental groups (n=10): 1 – intact;  
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2 – endotoxin-induced endothelial dysfunction 
(EIED). 3 – EIED + L-arginine 200 mg/kg; 4 – EIED 
+ Simvastatin 8.5 mg/kg; 5 – EIED + Atorvastatin  
4.3 mg/kg; 6 – EIED + Rosuvastatin8.5 mg/kg; 7 – 
EIED + Nanoparticulated rosuvastatin 11.6 mg/kg;  
8 – EIED + Simvastatin 8.5 mg/kg + L-arginine  
200 mg/kg; 9 – EIED + Atorvastatin 4.3 mg/kg +  
L-arginine 200 mg/kg; 10 – EIED + Rosuvastatin8.5 
mg/kg + L-arginine 200 mg/kg; 11 – EIED + 
Nanoparticulated rosuvastatin 11.6 mg/kg +  
L-arginine 200 mg/kg;  
On day 8 of the experiment, a catheter was 
inserted under anesthesia (chloral hydrate 300 mg/kg) 
into the left carotid artery to record blood pressure 
(BP); bolus administration of pharmacological agents 
was into the femoral vein. Hemodynamic parameters: 
systolic blood pressure (SBP), diastolic blood 
pressure (DBP) and heart rate (HR) were measured 
continuously with the use of "Biopac" hardware and 
software system. In addition to blood pressure 
measurements a series of functional tests was carried 
out in the following sequence: 1. Test for 
endothelium-dependent vascular relaxation 
(intravenous solution of acetylcholine (ACh) at a 
dose of 40 mg/kg at the rate of 0.1 ml per 100 g).  
2. Test for endothelium-independent vascular 
relaxation (intravenous solution of sodium 
nitroprusside (NP) at a dose of 30 mg/kg at the rate of 
0.1 ml per 100 g) [7-13, 16].   
The degree of endothelial dysfunction in 
experimental animal, as well as the degree of its 
correction with the studied medications was assessed 
by the estimated coefficient of endothelial 
dysfunction (EDC) [7-13, 16]. 
For the evaluation of cardioprotective activity, 
functional tests on adrenoreactivity [7-13] and the 
exhaustion of myocardial reserve were performed  
[7-13]. 
The dynamics of biochemical markers values 
(Total NO, eNOS expression, C-reactive protein, 
IL-6, TNF) in animals with endotoxin-induced 
endothelial dysfunction was assessed with the 
standard set of reagents [10]. 
The significance of changes in absolute 
parameters was determined by the difference method 
of variation statistics with finding the average values 
of the shifts (M), the arithmetic mean (±m) and the 
probability of possible error (p) by using the Student 
tables. Differences were evaluated as significant at 
p<0.05. Statistical calculations were performed with 
Microsoft Excel 7.0. 
Results: Monotherapy with NO donor  
L-arginine (200 mg/kg) daily intraperitoneally on the 
background of EIED modeling normalized EDC and 
insignificantly affected the BP values (Table 1). The 
HMG-Co-A reductase inhibitors simvastatin  
(8.5 mg/kg), atorvastatin (4.3 mg/kg), rosuvastatin 
(8.5 mg/kg) and nanoparticulated rosuvastatin  
(11.6 mg/kg) at the most effective doses improved 
significantly EDC and had no effect on blood 
pressure (Table 1). 
The combined use of L-arginine with HMG-Co-A 
reductase inhibitors simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin showed 
the most pronounced endothelium-protective effect, and 
the hemodynamic parameters such as systolic and 
diastolic blood pressure and EDC were not statistically 
different from those in intact animals (Table 1). 
At the same time, there was positive dynamics of 
contractility indicators during exercise testing in 
animals with EIED (Table 2).  For example, we 
detected the prevention of increase in adrenoreactivity 
and reduction in myocardial reserve both when using  
L-arginine and under its concomitant use with HMG-
Co-A reductase inhibitors simvastatin, atorvastatin, 
rosuvastatin and nanoparticulated rosuvastatin. In this 
case, as well as for EDC, the combined use of drugs has 
resulted in values not differing from those in intact 
animals (Table 2). 
The most pronounced endothelium- and 
cardioprotective effect of combined use of the NO 
donor L-arginine with HMG-Co-A reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin was on values of 
biochemical markers in EIED animals (Table 3). 
The protective effect of combined use of the NO 
donor L-arginine with HMG-Co-A reductase 
inhibitors simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin was most significant on 
the level of C-reactive protein and values of pro-
inflamatory cytokines IL-6 and TNF, which values 
did not differ from those in intact animals (Table 3). 
Conclusion: using the combined application of 
L-arginine with HMG-Co-A reductase inhibitors 
simvastatin, atorvastatin, rosuvastatin and 
nanoparticulated rosuvastatin on the background of 
modeling of sepsis-induced disease through the 
introduction of strain 603 Staphylococcusaureus 
shows endotelio- and cardioprotective effects, 
manifesting itself in preventing the proliferation of 
endothelial dysfunction coefficient (CED), 
adrenoreactivity, maintenance of myocardial reserve 
and the normalization of biochemical markers values 
(Total NO, eNOS expression, C-reactive protein,  
IL-6, TNF). In this case, the combined therapy was 
so effective that the values obtained thereunder did 
not differ from those obtained from control animals. 
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Table 1 
Influence of combined use of L-arginine with an HMG-CoA reductase inhibitor simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin on the dynamics of hemodynamic parameters in animals with endotoxin-induced 
endothelial dysfunction (M ± m, n = 10) 
 
Groups of animals SBP DBP EDC 
Intact  129.4±2.2 89.2± 1.1 1.1 ± 0.1 
Endotoxin-induced endothelial dysfunction (EIED) (n=10) 117.6±2.3* 85.0±2.1 3.7±0.5* 
EIED + L-arginine 200 mg/kg (n=10) 118.5±2.1 76.3±2.1 2.1±0.3*# 
EIED + Simvastatin 8.5 mg/kg (n=10) 127.3±2.8 87.1±1.9 2.3±0.5*# 
EIED + Atorvastatin 4.3 mg/kg (n=10) 130.0±3.3 85.8±2.2 2.1±0.3*# 
EIED + Rosuvastatin 8.5 mg/kg (n=1) 135.0±3.8 83.1±2.1 1.7±0.5*# 
EIED + Nanoparticulated rosuvastatin 11.6 mg/kg (n=10) 129.6±4.3 84.9±2.0 1.5±0.2*# 
EIED + L-arginine 200 mg/kg + Simvastatin 8.5 mg/kg (n=10) 142.4±3.1 94.2±2.2 1.6±0.3*# 
EIED + L-arginine 200 mg/kg + Atorvastatin 4.3 mg/kg (n=10) 137.8±3.4 92.5±2.3 1.5±0.3*# 
EIED + L-arginine 200 mg/kg + Rosuvastatin 8.5 mg/kg (n=10) 136.9±3.3 91.1±2.1 1.7±0.4*# 
EIED + L-arginine 200 mg/kg + Nanoparticulated rosuvastatin 11.6 mg/kg 
(n=10) 137.4±3.6 94.3±2.3 1.5±0.2
*#
 
 
Note: SBP – systolic blood pressure (mm Hg), DBP - diastolic blood pressure (mm Hg), EDC – endothelial dysfunction 
coefficient (rel. unit), * – significant difference with the intact group (p<0.05); # – significant difference with the group of 
animals with endotoxin-induced endothelial dysfunction (EIED) (p<0.05). 
 
Table 2 
Influence of combined use of L-arginine with an HMG-CoA reductase inhibitor simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin on the dynamics of contractility parameters during exercise testing in animals with 
endotoxin-induced endothelial dysfunction (EIED) (M ± m, n = 10) 
 
Group of animals 
Adrenoreactivity 
(mm Hg) 
Myocardial reserve 
exhaustion (%) 
Intact  201.5±9.4 112.7±10.9 
Endotoxin-induced endothelial dysfunction (EIED) (n=10) 240.3±8.7* 79.4±3.9* 
EIED + L-arginine 200 mg/kg (n=10) 211.4±7.8* 92.4±5.7* 
EIED + Simvastatin 8.5 mg/kg (n=10) 232.0±8.9* 87.4±3.7* 
EIED + Atorvastatin 4.3 mg/kg (n=10) 222.1±8.5*# 97.0±4.9* 
EIED + Rosuvastatin 8.5 mg/kg (n=1) 221.0±8.4*# 109.4±5.7*# 
EIED + Nanoparticulated rosuvastatin 11.6 mg/kg (n=10) 219.1±8.7*# 99.9±6.3*# 
EIED + L-arginine 200 mg/kg + Simvastatin 8.5 mg/kg (n=10) 204.8±6.9*# 109.7±4.8*# 
EIED + L-arginine 200 mg/kg + Atorvastatin 4.3 mg/kg (n=10) 201.0±5.3*# 107.6±3.5*# 
EIED + L-arginine 200 mg/kg + Rosuvastatin 8.5 mg/kg (n=10) 193.8±5.8*# 108.4±4.8*# 
EIED + L-arginine 200 mg/kg + Nanoparticulated rosuvastatin 11.6 mg/kg (n=10) 196.7±5.7*# 110.5±5.6*# 
 
Note: * – significant difference with the intact group (p<0.05); # – significant difference with the group of animals with 
endotoxin-induced endothelial dysfunction (EIED) (p<0.05). 
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Table 3 
Influence of combined use of L-arginine with an HMG-CoA reductase inhibitor simvastatin, atorvastatin, rosuvastatin 
and nanoparticulated rosuvastatin on the dynamics of biochemical markers values (Total NO, eNOS expression,  
C-reactive protein, IL-6, TNF) in animals with endotoxin-induced endothelial dysfunction (EIED) (M ± m, n = 10) 
 
Group of animals NOх 
ENOS 
Expression 
CRP level IL-6 TNF 
Intact  116.8±10.3 5.4±0.21 0.05±0.01 0.43±0.17  8.42±2.51 
Endotoxin-induced endothelial dysfunction 
(EIED) (n=10) 
182.3±12.4* 0.04±0.01* 0.38±0.01* 6.87±1.93* 17.83±3.79* 
EIED + L-arginine 200 mg/kg (n=10) 132.7±11.3*# 2.14±0.22*# 0.17±0.02*# 2.23±1.67*# 10.23±2.08*# 
EIED + Simvastatin 8.5 mg/kg (n=10) 122.9±8.4*# 1.93±0.12*# 0.08±0.01*# 1.03±0.62*# 10.76±1.70*# 
EIED + Atorvastatin 4.3 mg/kg (n=10) 130.0±10.9*# 2.07±0.21*# 0.09±0.01*# 1.27±0.33*# 9.89±1.79*# 
EIED + Rosuvastatin 8.5 mg/kg (n=1) 122.1±9.9*# 3.04±0.35*# 0.11±0.01*# 1.17±0.33*# 10.80±1.99*# 
EIED + Nanoparticulated rosuvastatin 11.6 
mg/kg (n=10) 
132.1±10.3*# 4.01±0.56*# 0.18±0.01*# 1.48±0.24*# 9.56±1.87*# 
EIED + L-arginine 200 mg/kg + Simvastatin  
8.5 mg/kg (n=10) 
123.5±9.7*# 4.12±0.65*# 0.08±0.02*# 0.92±0.12*# 9.12±1.12*# 
EIED + L-arginine 200 mg/kg + Atorvastatin  
4.3 mg/kg (n=10) 
121.7±9.5*# 4.23±0.69*# 0.07±0.02*# 0.90±0.13*# 8.79±0.91*# 
EIED + L-arginine 200 mg/kg + Rosuvastatin  
8.5 mg/kg (n=10) 
119.5±9.3*# 4.47±0.72*# 0.06±0.02*# 0.78±0.11*# 8.42±0.87*# 
EIED + L-arginine 200 mg/kg + Nanoparticulated 
rosuvastatin 11.6 mg/kg (n=10) 
117.8±10.0*# 4.92±0.86*# 0.06±0.02*# 0.63±0.10*# 7.56±0.79*# 
Note: NOx - end metabolites NO (µmol/l); eNOS expression (%); CRP level - level of C-reactive protein (mg/l); 
IL-6 – Interleukin 6 (pg/ml); TNF – tumor necrosis factor (pg/ml); * – significant difference with the intact group (p<0.05);  
# – significant difference with the group of animals with endotoxin-induced endothelial dysfunction (EIED) (p<0.05). 
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